Cargando…

Impact of labile plasma iron and iron chelation on the viability of cultured mononuclear cells from patients undergoing autologous hematopoietic stem cell transplantation

Detalles Bibliográficos
Autores principales:	Naoum, Flávio Augusto, Espósito, Breno Pannia, Zotarelli Filho, Idiberto José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503892/ https://www.ncbi.nlm.nih.gov/pubmed/28698851 http://dx.doi.org/10.5045/br.2017.52.2.135

Ejemplares similares

Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron
por: Alta, Roxana Y. P., et al.
Publicado: (2017)

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
por: Pai, AB, et al.
Publicado: (2017)

Iron deficiency in cancer patients
por: Naoum, Flávio Augusto
Publicado: (2016)

Hydroxytyrosol inhibits hydrogen peroxide-induced apoptotic signaling via labile iron chelation
por: Kitsati, Natalia, et al.
Publicado: (2016)

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children
por: Lee, J W, et al.
Publicado: (2009)

Iron Metallodrugs: Stability, Redox Activity and Toxicity against Artemia salina
por: Vitorino, Hector Aguilar, et al.
Publicado: (2015)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

Design of a water-soluble chitosan-based polymer with antioxidant and chelating properties for labile iron extraction
por: Grange, Coralie, et al.
Publicado: (2023)

Adjusting thresholds of serum ferritin for iron deficiency: a moving target()
por: Naoum, Flávio Augusto
Publicado: (2017)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Iron-tracking strategies: Chaperones capture iron in the cytosolic labile iron pool
por: Philpott, Caroline C., et al.
Publicado: (2023)

Labile iron in cells and body fluids: physiology, pathology, and pharmacology
por: Cabantchik, Zvi Ioav
Publicado: (2014)

Labile iron accumulation augments T follicular helper cell differentiation
por: Scindia, Yogesh, et al.
Publicado: (2022)

A facile colorimetric method for the quantification of labile iron pool and total iron in cells and tissue specimens
por: Abbasi, Usama, et al.
Publicado: (2021)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

Magnetospirillum magneticum as a Living Iron Chelator Induces TfR1 Upregulation and Decreases Cell Viability in Cancer Cells
por: Menghini, Stefano, et al.
Publicado: (2021)

The Impact of Iron Chelators on the Biology of Cancer Stem Cells
por: Szymonik, Julia, et al.
Publicado: (2021)

The iron chelator deferoxamine decreases myeloma cell survival
por: Yang, Feifei, et al.
Publicado: (2021)

The Labile Iron Pool Reacts Rapidly and Catalytically with Peroxynitrite
por: Condeles, André Luís, et al.
Publicado: (2021)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

Cancer cell death induced by ferritins and the peculiar role of their labile iron pool
por: Cutrin, Juan Carlos, et al.
Publicado: (2018)

Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron with Severity Infection
por: Bastin, Alireza, et al.
Publicado: (2021)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Reversing oncogenic transformation with iron chelation
por: Abdelaal, Gina, et al.
Publicado: (2021)

Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)

The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells
por: Bailey, Danielle K., et al.
Publicado: (2021)

Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability
por: Jang, Hye Min, et al.
Publicado: (2022)

Therapeutic Potential of Iron Chelating Therapy: Modification of Disease by Iron Depletion
por: Hershko, Chaim, et al.
Publicado: (1994)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

Iron Pathways and Iron Chelation Approaches in Viral, Microbial, and Fungal Infections
por: Chhabra, Ravneet, et al.
Publicado: (2020)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells
por: Asperti, Michela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_abns25suuo96kp42n9ptlg2824